Zoetis Inc. (ZTS)
NYSE: ZTS · Real-Time Price · USD
122.57
-1.87 (-1.50%)
At close: Dec 3, 2025, 4:00 PM EST
122.99
+0.42 (0.34%)
After-hours: Dec 3, 2025, 7:50 PM EST
Zoetis Revenue
Zoetis had revenue of $2.40B in the quarter ending September 30, 2025, with 0.50% growth. This brings the company's revenue in the last twelve months to $9.40B, up 2.68% year-over-year. In the year 2024, Zoetis had annual revenue of $9.26B with 8.33% growth.
Revenue (ttm)
$9.40B
Revenue Growth
+2.68%
P/S Ratio
5.82
Revenue / Employee
$680,942
Employees
13,800
Market Cap
54.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.26B | 712.00M | 8.33% |
| Dec 31, 2023 | 8.54B | 464.00M | 5.74% |
| Dec 31, 2022 | 8.08B | 304.00M | 3.91% |
| Dec 31, 2021 | 7.78B | 1.10B | 16.49% |
| Dec 31, 2020 | 6.68B | 415.00M | 6.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ZTS News
- 1 day ago - Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript - Seeking Alpha
- 1 day ago - Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast - Business Wire
- 1 day ago - Top 15 High-Growth Dividend Stocks For December 2025 - Seeking Alpha
- 2 days ago - 2 Stocks to Buy Near Their 52-Week Lows - The Motley Fool
- 7 days ago - Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs - Business Wire
- 12 days ago - Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst - Benzinga
- 13 days ago - Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 14 days ago - Zoetis to Host Innovation Webcast - Business Wire